Klaus Schabert appointed COO and Member of the Executive Board of RAUMEDIC AG

Helmbrechts, Germany - The Supervisory Board of RAUMEDIC AG, a leading global provider of polymer-based product solutions for the medical and pharmaceutical industries, has appointed Klaus Schabert as Chief Operating Officer (COO) and Member of the Executive Board. Schabert succeeds Martin Schenkel in his functions as COO and Member of the Executive Board, which he had held since 2018.

Schabert joined RAUMEDIC as an experienced production expert in February 2022. Previously, as Executive Vice President Global Operations, he oversaw operations for the cosmetics division at Faber Castell. In this role, he was responsible for several international production sites, where production was also carried out in compliance with GMP clean room standards. He has a total of 30 years of professional experience in various positions and areas of the Faber Castell Group, including more than 25 years in various management positions.

Stefan Seuferling, CEO and Chairman of the Executive Board of RAUMEDIC AG, emphasizes the experience and expertise of the new COO, which was one of the decisive factors for the appointment to the executive board: "Klaus Schabert has extensive experience in the executive and strategic management of several plants. In addition, he is characterized by excellent knowledge in the areas of production control, supply chain management, logistics, industrial engineering, procurement and technical developments."

According to Seuferling, Schabert has already successfully demonstrated his operations expertise in his previous role at RAUMEDIC: "As Global Vice President Operations at RAUMEDIC, Klaus Schabert has used his skills effectively, purposefully and profitably. I am certain that he will make a very significant and tangible contribution to the development of the company as a Member of the Executive Board and COO."

About RAUMEDIC

RAUMEDIC develops solutions for life. Together with its customers, the medical technology company breaks new ground to improve the diagnosis and therapy of diseases. In doing so, RAUMEDIC focuses on polymer-based solutions for medical and pharmaceutical applications as well as products for intensive care. RAUMEDIC is represented worldwide and employs around 1,200 people at five production sites. In the core markets of Europe and North America, the company produces in its own clean room manufacturing facilities.